Rein Therapeutics, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE8-KRein Therapeutics, Inc.RNTXSep 4

   Current report

2. ROUTINE8-KRein Therapeutics, Inc.RNTXAug 27

   Current report

3. ROUTINESCHEDULE 13GRein Therapeutics, Inc.RNTXAug 14

   Ownership stake disclosure by ADAR1 Capital Management, LLC

   ADAR1 Capital Management, LLC, filed by

4. ROUTINESCHEDULE 13G/ARein Therapeutics, Inc.RNTXAug 14

   Ownership stake disclosure by Lynwood Capital Management Inc. (amended)

   Lynwood Capital Management Inc., filed by

5. NOTABLE10-QRein Therapeutics, Inc.RNTXAug 14

   Quarterly report

6. ROUTINESCHEDULE 13G/ARein Therapeutics, Inc.RNTXAug 13

   Ownership stake disclosure by Laurence W Lytton (amended)

   Laurence W Lytton, filed by

7. ROUTINE8-KRein Therapeutics, Inc.RNTXJul 21

   Current report

8. ROUTINESCHEDULE 13G/ARein Therapeutics, Inc.RNTXJul 14

   Ownership stake disclosure by Voss Capital, LP (amended)

   Voss Capital, LP, filed by

9. ROUTINEDEFA14ARein Therapeutics, Inc.RNTXJun 8

   Additional proxy materials

10. ROUTINEARSRein Therapeutics, Inc.RNTXJun 8

    Annual report to shareholders

11. ROUTINEDEF 14ARein Therapeutics, Inc.RNTXJun 8

    Proxy statement

12. ROUTINE4Rein Therapeutics, Inc.RNTXMay 28

    Rickenbach Josef H Von, insider filing for RNTX

    Rickenbach Josef H Von, reporting

13. ROUTINEPRE 14ARein Therapeutics, Inc.RNTXMay 28

    Preliminary proxy statement

14. NOTABLE10-QRein Therapeutics, Inc.RNTXMay 15

    Quarterly report

15. ROUTINE4Rein Therapeutics, Inc.RNTXMay 13

    James Brian Windsor, insider filing for RNTX

    James Brian Windsor, reporting

16. ROUTINESCHEDULE 13G/ARein Therapeutics, Inc.RNTXMay 8

    Ownership stake disclosure by BIOS Fund I, LP (amended)

    BIOS Fund I, LP, filed by

17. ROUTINESCHEDULE 13GRein Therapeutics, Inc.RNTXMay 8

    Ownership stake disclosure by Lynwood Capital Management Inc.

    Lynwood Capital Management Inc., filed by

18. ROUTINESCHEDULE 13GRein Therapeutics, Inc.RNTXMay 7

    Ownership stake disclosure by Funicular Funds, LP

    Funicular Funds, LP, filed by

19. ROUTINESCHEDULE 13GRein Therapeutics, Inc.RNTXMay 6

    Ownership stake disclosure by Laurence W Lytton

    Laurence W Lytton, filed by

20. ROUTINE8-KRein Therapeutics, Inc.RNTXMay 4

    Current report

21. ROUTINE424B5Rein Therapeutics, Inc.RNTXMay 4

    Securities offering

22. NOTABLES-1Rein Therapeutics, Inc.RNTXApr 28

    Securities offering

23. ROUTINE10-K/ARein Therapeutics, Inc.RNTXApr 27

    Annual report (amended)

24. NOTABLE10-KRein Therapeutics, Inc.RNTXMar 26

    Annual report

25. ROUTINE8-KRein Therapeutics, Inc.RNTXMar 2

    Current report

26. ROUTINE8-KRein Therapeutics, Inc.RNTXFeb 19

    Current report

27. ROUTINESCHEDULE 13G/ARein Therapeutics, Inc.RNTXFeb 13

    Ownership stake disclosure by Voss Capital, LP (amended)

    Voss Capital, LP, filed by

28. ROUTINE8-KRein Therapeutics, Inc.RNTXJan 16

    Current report

29. ROUTINE8-KRein Therapeutics, Inc.RNTXDec 11, 2025

    Current report

30. ROUTINE4Rein Therapeutics, Inc.RNTXNov 19, 2025

    Rein Therapeutics, Inc. - Insider ownership filing (4)

    • Insider ownership filing (4)
    • Reports beneficial ownership changes

    Voss Capital, LP, reporting · Voss Advisors GP, LLC, reporting · +3 more

31. NOTABLE10-QRein Therapeutics, Inc.RNTXNov 14, 2025

    Quarterly report

32. ROUTINE8-KRein Therapeutics, Inc.Nov 3, 2025

    Current report

Older filings on EDGAR